Clinical study of a blood test shows 83% accuracy for detecting colorectal cancer
On Mar. 13, 2024, the Fred Hutchinson Cancer Center announced that a blood test intended for screening for…
Biotechnology | FDA | Therapeutics | Vaccine
Wegovy received FDA approval for cardiovascular risk reduction in adults with known heart disease or obesity
On Mar. 8, 2024, the U.S. Food and Drug Administration approved a new indication for use of Novo…
Hugel Received FDA Approval in the U.S. of Letybo (letibotulinumtoxinA-wlbg) for Injection for Treatment of Glabellar Lines
On Mar. 4, 2024, Hugel America announced it received U.S. Food and Drug Administration (FDA) approval on its…
New antibodies target ‘Dark Side’ of influenza virus protein
On Mar. 1, 2024, researchers at the National Institutes of Health (NIH) announced they had identified antibodies targeting…
CDC | COVID-19 | Therapeutics | Vaccine
CDC Advisory Committee recommended older adults able to receive additional dose of updated COVID-19 vaccine
On Feb. 28, 2024, the CDC Advisory Committee on Immunization Practices’ (ACIP) announced a recommendation for adults ages…
California’s Stem Cell Agency awarded $56 million for clinical research, $21.3 million for Shared Labs program
On Feb. 23, 2024, the California Institute for Regenerative Medicine (CIRM) awarded $56 million to fund various clinical…
First Tissue Bank May Help Solve Mystery of Long COVID Misery
On Feb. 22, 2024, the University of California, San Francisco (UC, San Francisco) launched the world’s first tissue…
CPRIT approved almost $100 million in grants to advance the fight against cancer in Texas
On Feb. 21, 2024, the Cancer Prevention and Research Institute of Texas (CPRIT) announced it had approved $98,592,155…
Fred Hutch to lead new federal Cancer Screening Research Network
On Feb. 21, 2024, the Fred Hutchinson Cancer Center announced it was at the helm of a new…
Biotechnology | Disease | FDA | Therapeutics
FDA approved Xolair as first and only medicine for children and adults with one or more food allergies
On Feb. 16. 2024, Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair…
FDA approved first medication to treat severe frostbite
On Feb. 14, 2024, the U.S. Food and Drug Administration (FDA) approved Eicos Sciences’ Aurlumyn (iloprost) injection to…
European Commission approved first CRISPR/Cas9 gene-edited therapy, CASGEVY for reatment of SCD and TDT
On Feb. 13, 2024, CRISPR Therapeutics announced that the European Commission had granted conditional marketing authorization to CASGEVY…
Alaska Department of Health confirmed first fatal case of Alaskapox virus
On Feb. 9, 2024, the state of Alaska Department of Health Alaska Department of Health confirmed the first…
Deschutes County confirmed case of human plague in local resident
On Feb. 8, 2024, Deschutes County Health Services in Bend, Oregon confirmed a case of human plague in…
China builds world’s most detailed human genome with ‘enormous’ implications for disease treatment
On Feb. 2, 2024, Chinese scientists announced they have assembled the world’s most detailed human genome yet, a…
Gene study identifies DNA variants linked to dyslexia
On Jan. 25, 2024, a study led by the University of Edinburgh, is the largest genetic study of…
Biotechnology | COVID-19 | Diagnostics | Disease | Neurology | Therapeutics
Washington University’s Jeffrey T. Fort Neuroscience Research building dedicated
On Jan. 25, 2024, dozens of noted scientists, philanthropists, and Washington University, state and local leaders celebrated the…
Small robot made big difference for cochlear implant patient at Oregon Health & Science University
On Jan. 24, 2024, Oregon Health & Science University announced that Pamela Runner, 77, of Corvallis, became the…
Biotechnology | CRISPR | Disease | FDA | Therapeutics
CRISPR Therapeutics announced FDA approval of CASGEVY for treatment of ransfusion-dependent beta thalassemia
On Jan. 16, 2024, the U.S. Food and Drug Administration (FDA) announced it had approved CRISPR Therapeutics’ CASGEVY…
Biotechnology | Disease | FDA | Therapeutics
Swissmedic Authorises CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
Biotechnology | Diagnostics | Disease | NIH | Therapeutics | Women's Health
NIH-supported researchers created single-cell atlas of the placenta during term labor
On Jan. 10, 2024, an National Institutes of Health (NIH) supported study announced an n atlas revealing the…
‘LEQEMBI’ (Lecanemab) approved for treatment of Alzheimer’s disease in China
On Jan. 9, 2024, Biogen and Eisai announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody ‘LEQEMBI’…
Molecular jackhammers’ ‘good vibrations’ eradicate cancer cells
On Dec. 19, 2023, a research team led by Rice University reported they found that the atoms of…
ZURZUVAE (zuranolone) CIV, a landmark treatment for women with postpartum Depression, available in the U.S.
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
Artificial Intelligence | Biotechnology | Diagnostics | Disease | Genomics | Nanotechnology | Neurology | Non-Profit Research | Pharmaceutical | Therapeutics
PNNL created Center for Artificial Intelligence
On Dec. 14, 2023, the Department of Energy’s (DOE) Pacific Northwest National Laboratory (PNNL) announced that it had…
Biotechnology | Diagnostics | Disease | Genomics | Neurology | Therapeutics
Alberta researchers revealed full structure of ‘ancient genetic parasite’ implicated in human diseases
On Dec. 14, 2023, the University of Alberta announced that a study published in Nature sheds light on…
Biotechnology | Diagnostics | Disease | NIH | Therapeutics
Scientists unveiled complete cell map of a whole mammalian brain
On Dec. 13, 2023, for the first time ever, an international team of researchers announced they had created…
CRISPR | Genomics | Stem Cell | Therapeutics
FDA approved first gene therapies to treat patients with sickle cell disease
On Dec. 8, 2023, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing…
Biotechnology | CRISPR | FDA | Genomics | Therapeutics
Vertex and CRISPR Therapeutics announced U.S. FDA approval of CASGEVY for treatment of sickle Cell disease
On Dec. 8, 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the U.S. Food and Drug Administration (FDA)…
bluebird bio announced commercial launch of LYFGENIA’ gene therapy for patients ages 12 and older with sickle cell disease
On Dec. 8, 2023, bluebird bio announced the U.S. commercial launch of its LYFGENIA’ (lovotibeglogene autotemcel, also known…